The number of venture-backed life science companies going public neared a peak set in 2000 during the 2nd quarter, raising $2.2 billion and doubling the volume and value of IPOs from the 1st quarter, according to the National Venture Capital Assn. and Thomson Reuters.
There were also 83 venture-backed acquisitions during the quarter, down 59% compared with Q2 2012, according to the groups’ Exit Poll report.